PARP1 and ovarian cancer: A multicenter Phase II trial enrolled patients with platinum-sensitive recurrent ovarian cancer and randomized them to receive either the combination of the PARP inhibitor olaparib with paclitaxel and carboplatin or chemotherapy alone.